ASLAN Pharmaceuticals, a clinical-stage oncology-focused biopharmaceutical company, is restructuring to focus its resources on its lead clinical programs: varlitinib in biliary tract cancer (BTC), ASLAN003 in acute myeloid leukaemia (AML), and ASLAN004 in atopic dermatitis. ASLAN will reduce its headcount by 30%. In total, the planned changes will lower operational costs by 50%. ASLAN will focus its resources on the late-stage development of varlitinib as a potential novel treatment for first...